- Home
- AURA vs ARCT Comparison
AURA vs ARCT Comparison
Compare AURA & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURA
- ARCT
- Stock Information
- Founded
- AURA 2007
- ARCT 2013
- Country
- AURA United States
- ARCT United States
- Employees
- AURA N/A
- ARCT N/A
- Industry
- AURA Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- AURA Health Care
- ARCT Health Care
- Exchange
- AURA Nasdaq
- ARCT Nasdaq
- Market Cap
- AURA 370.1M
- ARCT 298.3M
- IPO Year
- AURA 2021
- ARCT N/A
- Fundamental
- Price
- AURA $5.23
- ARCT $10.98
- Analyst Decision
- AURA Strong Buy
- ARCT Strong Buy
- Analyst Count
- AURA 4
- ARCT 7
- Target Price
- AURA $22.75
- ARCT $57.80
- AVG Volume (30 Days)
- AURA 168.0K
- ARCT 372.7K
- Earning Date
- AURA 05-20-2025
- ARCT 05-12-2025
- Dividend Yield
- AURA N/A
- ARCT N/A
- EPS Growth
- AURA N/A
- ARCT N/A
- EPS
- AURA N/A
- ARCT N/A
- Revenue
- AURA N/A
- ARCT $152,310,000.00
- Revenue This Year
- AURA N/A
- ARCT N/A
- Revenue Next Year
- AURA N/A
- ARCT $44.93
- P/E Ratio
- AURA N/A
- ARCT N/A
- Revenue Growth
- AURA N/A
- ARCT N/A
- 52 Week Low
- AURA $4.84
- ARCT $8.04
- 52 Week High
- AURA $12.38
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- AURA 42.97
- ARCT 42.59
- Support Level
- AURA $4.94
- ARCT $10.70
- Resistance Level
- AURA $6.29
- ARCT $13.10
- Average True Range (ATR)
- AURA 0.44
- ARCT 0.83
- MACD
- AURA 0.02
- ARCT -0.05
- Stochastic Oscillator
- AURA 21.48
- ARCT 9.46
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.